Leadership Change at Viatris#
Viatris Inc., a pharmaceutical company based in Pittsburgh, has announced that Chief Financial Officer Theodora "Doretta" Mistras will be leaving the company for a new opportunity. She will remain with Viatris until May 22 to ensure a smooth transition.
Paul Campbell Steps In#
Paul Campbell, who is currently the Chief Accounting Officer and Corporate Controller, will take over as interim Chief Financial Officer starting May 8. Campbell brings over 20 years of experience in accounting and financial operations to the role. He has been with Mylan, a predecessor of Viatris, since 2002, and has held various positions in internal audit, business development, and finance operations. Campbell holds a Bachelor of Science in Accounting from Pennsylvania State University.
Company Performance and Future Outlook#
Viatris has seen a significant increase in its stock value, rising 82% over the past year, with shares currently trading at $15.21. The company is preparing to release its financial results for the first quarter of 2026 on May 7, with analysts expecting earnings of $2.44 per share. Viatris has ambitious financial targets, aiming for annual revenue growth of 5% to 6% through 2030, and expects adjusted earnings per share to rise by 9% to 10% during this period.
Recent Developments#
In addition to the leadership change, Viatris has received approval from Japan’s Ministry of Health, Labour and Welfare for Effexor SR capsules to treat generalized anxiety disorder in adults. This marks the first approved treatment for this condition in Japan. The company is also preparing to present data on a new hormonal contraceptive patch at an upcoming medical meeting.